Metoclopramide inhibits proliferation of leukemia stem cells

A research team at Inselspital, Bern University Hospital and the University of Bern has identified and tested the use of an agent that can effectively inhibit the proliferation of leukemia stem cells. Metoclopramide (MPR), used as an anti-emetic medication, interrupts the unique CD93 signaling pathway that only leukemia stem cells use to proliferate. This opens up a therapeutic approach using MPR to selectively eliminate leukemia stem cells.